ArticleInternational urology and nephrology2026
Naringenin protects against renal ischemia-reperfusion injury following unilateral nephrectomy via modulation of oxidative stress and kisspeptin expression.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRenal ischemia-reperfusion (IR) injury is a major cause of acute kidney injury, mediated by oxidative stress (OS), inflammation, and apoptosis. Naringenin (NRG), a citrus flavonoid, exerts antioxidant and anti-apoptotic actions, yet its role in renal kisspeptin signaling during IR injury remains unexplored. This study investigated the protective effects of NRG on renal IR injury in rats, with emphasis on OS, apoptosis, and kisspeptin expression.
methodsThirty-two female Wistar albino rats were randomized into four groups: sham, IR, NRG/IR (100 mg/kg NRG administered 2 h before ischemia), and IR/NRG (NRG given at reperfusion). Following right nephrectomy and 60 min ischemia of the left kidney, reperfusion was allowed for 24 h. Serum (blood urea nitrogen, creatinine, albumin), tissue OS markers, histopathology, and immunohistochemical expression of kisspeptin, Bcl-2-associated X (Bax), and B cell lymphoma 2 (Bcl-2) were evaluated.
resultsIR markedly increased malondialdehyde and reduced superoxide dismutase and catalase activities, accompanied by tubular degeneration, congestion, and dilatation. NRG treatment significantly reversed these biochemical and histological changes. Pre-ischemic NRG enhanced Bcl-2 immunoreactivity, while post-ischemic administration restored kisspeptin expression. Bax expression showed only mild non-significant increases. Notably, post-treatment provided superior recovery of kisspeptin signaling and structural preservation, whereas pre-treatment more effectively enhanced anti-apoptotic protein expression.
conclusionNRG confers renoprotection against IR injury by reducing OS, preserving renal architecture, and modulating apoptosis-related proteins. A novel finding is the restoration of kisspeptin expression by NRG, particularly when administered at reperfusion, suggesting timing-dependent therapeutic potential.
Indexed as
Identifiers
42490039What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.